Glenmark Pharmaceuticals completed the purchase of two NBEs from Chromos Molecular Systems. CHR-1103 and CHR-1201 are humanized mAbs.
Under the terms of the transaction, Glenmark bought all rights to the products as well as rights to use Chromos' ACE System technology for cell-line development for use with respect to CHR-1103 and CHR-1201. Glenmark holds the worldwide rights for further development, registration, and commercialization of these products.
CHR-1103 and CHR-1201 are part of a validated class of drugs known as SAMIs, or selective adhesion molecule inhibitors. CHR-1103 is an anti-inflammatory agent with a novel mechanism of action, being developed initially to treat acute multiple sclerosis. Glenmark plans to initiate Phase I trials in 2008.
CHR-1201 is an antithrombolytic, which Glenmark plans to develop initially to treat acute stroke. The company expects to start Phase I on CHR-1201 by March 2009.